CytRx inks securities purchase agreement for $10M

Jul. 13, 2021 8:36 AM ETCytRx Corporation (CYTR)CYTRBy: Mamta Mayani, SA News Editor1 Comment
  • CytRx (OTCQB:CYTR) has entered into a securities purchase agreement with healthcare-focused institutional investor for aggregate gross proceeds of ~$10M.
  • Under the terms of the agreement, CytRx has agreed to sell 2M shares of common stock at $0.88/share for gross proceeds of ~$1.76M in a registered direct offering and 8,240 shares of Series C 10.00% Convertible Preferred Stock at $1,000/share for gross proceeds of ~$8.24M, in a concurrent private placement.
  • The Preferred Stock will be convertible into an aggregate of up to 9,363,637 common shares at $0.88/share.
  • CytRx will also issue to the Investor an unregistered preferred investment option for a term of five and one-half years, that allows for the purchase of up to 11,363,637 common shares for additional gross proceeds of ~$10M if exercised in full.
  • Net proceeds will be used for working capital purposes.
  • The registered direct offering and concurrent private placement are expected to close on July 15, 2021.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.